A detailed history of Cibc World Markets Corp transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Cibc World Markets Corp holds 13,825 shares of LCTX stock, worth $9,539. This represents 0.0% of its overall portfolio holdings.

Number of Shares
13,825
Holding current value
$9,539
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 10, 2025

BUY
$0.5 - $0.95 $6,912 - $13,133
13,825 New
13,825 $6,000

Others Institutions Holding LCTX

About Lineage Cell Therapeutics, Inc.


  • Ticker LCTX
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 169,755,008
  • Market Cap $117M
  • Description
  • Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...
More about LCTX
Track This Portfolio

Track Cibc World Markets Corp Portfolio

Follow Cibc World Markets Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cibc World Markets Corp, based on Form 13F filings with the SEC.

News

Stay updated on Cibc World Markets Corp with notifications on news.